Motilal Oswal BSE Healthcare ETF-Growth
Equity: Sectoral-Pharma - Growth (Open ended) Factsheet
SEBI Riskometer: Very HighCategory: Equity: Sectoral-PharmaBenchmark: BSE Healthcare Total Return Index
₹50.39-0.27%
24 Jul 2026
Holdings Analysis
ETF constituent allocation snapshot — equity, sector concentration and market cap distribution for Motilal Oswal BSE Healthcare ETF-Growth.
Market Cap Distribution
Large Cap (32.3%)
Mid Cap (40.7%)
Small Cap (27.0%)
Historical Asset Allocation
| Asset | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Equity | 99.82% | 99.92% | 99.88% | 99.90% | 99.84% | 99.91% |
| Debt | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Others (incl. cash) | 0.18% | 0.08% | 0.12% | 0.10% | 0.16% | 0.09% |
| Commodities | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Real Estate | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Portfolio Snapshot
No. of Securities
126
P/E Ratio
41.61
P/B Ratio
5.36
Top Holding %
12.87%
Top 5 Holdings %
34.56%
Top 10 Holdings %
53.51%
AUM
₹42 Cr
Expense Ratio
0.43%
Since Inception
21.33%
Max Drawdown
-0.16%
Alpha
-0.25%
Sharpe Ratio
1.06
Top Portfolio Holdings by Weight
Latest portfolio holdings sorted by allocation weight. Includes instrument name, sector, number of shares, market value (₹ Cr) and percentage of net assets. Switch dates or categories using the controls below.
| Instrument | Sector | No. of Shares | Value (Rs. Cr) | Weight | Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Healthcare | 28,939 | 5.39 | 12.87% | -0.33%↓ |
| Apollo Hospitals Enterprise Ltd. | Healthcare | 2,737 | 2.38 | 5.68% | 0.01%↑ |
| Divis Laboratories Ltd. | Healthcare | 3,416 | 2.25 | 5.36% | -0.40%↓ |
| Max Healthcare Institute Ltd. | Healthcare | 19,829 | 2.24 | 5.35% | 0.51%↑ |
| Cipla Ltd. | Healthcare | 15,156 | 2.22 | 5.30% | -0.07%↓ |
| Dr. Reddys Laboratories Ltd. | Healthcare | 16,331 | 2.22 | 5.29% | -0.10%↓ |
| Lupin Ltd. | Healthcare | 6,496 | 1.57 | 3.75% | 0.01%↑ |
| Laurus Labs Ltd. | Healthcare | 10,274 | 1.56 | 3.72% | 0.13%↑ |
| Fortis Healthcare Ltd. | Healthcare | 13,963 | 1.34 | 3.19% | -0.10%↓ |
| Torrent Pharmaceuticals Ltd. | Healthcare | 2,722 | 1.26 | 3.00% | -0.03%↓ |
| Aurobindo Pharma Ltd. | Healthcare | 7,473 | 1.18 | 2.81% | 0.10%↑ |
| Glenmark Pharmaceuticals Ltd. | Healthcare | 4,009 | 0.88 | 2.11% | -0.20%↓ |
| Alkem Laboratories Ltd. | Healthcare | 1,570 | 0.87 | 2.09% | -0.10%↓ |
| Biocon Ltd. | Healthcare | 19,116 | 0.8 | 1.91% | -0.21%↓ |
| Mankind Pharma Ltd. | Healthcare | 2,988 | 0.76 | 1.82% | 0.02%↑ |
| Zydus Lifesciences Ltd. | Healthcare | 6,743 | 0.75 | 1.79% | -0.05%↓ |
| Ipca Laboratories Ltd. | Healthcare | 3,740 | 0.64 | 1.52% | 0.09%↑ |
| Aster DM Healthcare Ltd. | Healthcare | 7,083 | 0.56 | 1.33% | 0.02%↑ |
| Krishna Institute of Medical Sciences Ltd | Healthcare | 6,650 | 0.54 | 1.29% | 0.01%↑ |
| Gland Pharma Ltd. | Healthcare | 2,120 | 0.53 | 1.26% | 0.05%↑ |
1 / 7
Sector-wise Portfolio Allocation
Equity exposure by sector as a percentage of total net assets, tracked across recent portfolio dates. Identifies concentration risk and sector rotation trends in the fund's holdings.
| Sector | 30 Jun 2026 | 31 May 2026 | 30 Apr 2026 | 31 Mar 2026 | 28 Feb 2026 | 31 Jan 2026 |
|---|---|---|---|---|---|---|
| Healthcare | 99.38% | 99.46% | 99.36% | 99.44% | 99.36% | 99.37% |
| Services | 0.24% | 0.24% | 0.29% | 0.25% | 0.29% | 0.32% |
| Chemicals | 0.20% | 0.22% | 0.23% | 0.21% | 0.19% | 0.22% |
Equity Insights
A detailed look at the equity holdings of this scheme — aggregated scores on value, momentum, quality parameters along with diversification and performance analysis.
Style Analysis
Value score
28.9 / 100
Weighted average Value score is 28.9. This indicates that portfolio is relatively reasonably valued using composite of value measures.
Price Momentum score
77.0 / 100
Weighted average Price Momentum score is 77.0. This indicates that portfolio has high momentum using composite of momentum measures.
Quality score
84.1 / 100
Weighted average Quality score is 84.1. This indicates that portfolio has high quality using composite of quality measures.
QVM score
74.7 / 100
Weighted average QVM score is 74.7. This indicates that portfolio has average QVM score and hence a neutral stance is warranted.
Red Flags
Frequently Asked Questions
What are the top holdings of Motilal Oswal BSE Healthcare ETF-Growth?
The top holdings of Motilal Oswal BSE Healthcare ETF-Growth as of 30 Jun 2026 are Sun Pharmaceutical Industries Ltd. (12.87%), Apollo Hospitals Enterprise Ltd. (5.68%), Divis Laboratories Ltd. (5.36%), Max Healthcare Institute Ltd. (5.35%), Cipla Ltd. (5.30%). These top 5 stocks together account for 34.56% of the total portfolio. You can view the complete holdings breakdown above.
How many stocks does Motilal Oswal BSE Healthcare ETF-Growth hold in its portfolio?
Motilal Oswal BSE Healthcare ETF-Growth holds 126 stocks in its portfolio as of 30 Jun 2026. The fund's portfolio size reflects the fund manager's investment approach, a more concentrated portfolio indicates higher conviction bets, while a larger number of holdings suggests a more diversified strategy.
What is the sector allocation of Motilal Oswal BSE Healthcare ETF-Growth?
As of 30 Jun 2026, Motilal Oswal BSE Healthcare ETF-Growth's top sector allocations are Healthcare (99.38%), Services (0.24%), Chemicals (0.20%). You can find detailed sector allocation above.
What is the equity and debt allocation of Motilal Oswal BSE Healthcare ETF-Growth?
As of 30 Jun 2026, Motilal Oswal BSE Healthcare ETF-Growth has 99.82% allocated to equity, and 0.00% to debt. You can also check the historical trends above.
What is the market cap allocation of Motilal Oswal BSE Healthcare ETF-Growth?
As of 30 Jun 2026, Motilal Oswal BSE Healthcare ETF-Growth's market cap allocation is 32.27% in large caps, 40.72% in mid caps, and 27.01% in small caps.
What is the PE ratio of Motilal Oswal BSE Healthcare ETF-Growth's portfolio?
The portfolio PE ratio of Motilal Oswal BSE Healthcare ETF-Growth is 41.61 as of 30 Jun 2026. The portfolio PE ratio tells you how expensive or cheap the fund's holdings are relative to their earnings.
What is the credit quality of Motilal Oswal BSE Healthcare ETF-Growth?
A credit rating breakdown is not available for Motilal Oswal BSE Healthcare ETF-Growth — its non-equity allocation was 0.00% as of the latest disclosure. This is common when a fund's non-equity holdings are mostly cash or short-term money market instruments, which aren't assigned a credit rating the way bonds are.
When is the latest portfolio disclosure for Motilal Oswal BSE Healthcare ETF-Growth?
The latest portfolio disclosure for Motilal Oswal BSE Healthcare ETF-Growth is as of 30 Jun 2026. SEBI requires all mutual funds to disclose their complete portfolio holdings on a monthly basis, typically within 10 days of the end of each month.